Welcome to the NRG Oncology eNewsletter
If you have a suggestion or would like to submit content to our Communications team, please email nrg-broadcasts@nrgoncology.org.
Facebook
Twitter
Instagram
Lung Cancer Awareness Highlight
NRG-LU005: Studying the Addition of Atezolizumab to Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer (LS-SCLC)
NRG-LU005 is a phase II/III trial that will enroll approximately 506 patients with limited-stage small cell lung cancer (LS-SCLC) and randomly assigning patients to receive either standard chemoradiotherapy (platinum/etoposide + thoracic radiation) by itself or standard chemotherapy with the immunotherapy drug atezolizumab IV on day 1 or 2 of each chemotherapy cycle followed my maintenance atezolizumab. 
Congratulations to the NRG-LU005 Team! 
NRG Oncology recently received a High Performance Letter from Meg Mooney, MD, MBA, the the Acting Associate Director of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, at the National Cancer Institute (NCI) and the Cheif of the Clinical Investigations Branch (CIB) in CTEP. Below is an excerpt from the letter:
“CTEP would like to congratulate all those who contributed to the efficient development and activation of protocol NRG-LU005, “ Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab.” This study was able to open to patient enrollment in 439 days, which was close to the OEWG target deadline of 300 days. We applaud the dedication and teamwork necessary to accomplish this goal and look forward to the efficient enrollment and successful completion of the trial.”
Congratulations to the NRG-LU005 study team and a thank you to everyone who contributed to this success.
In Memory of Bernard (Bernie) Fisher, MD 

Bernard Fisher, MD, 101, dies in Pittsburgh

Photo: University of Pittsburgh

The death of Bernard Fisher, MD, one of the founders of the National Surgical Adjuvant Breast and Bowel Project and a visionary researcher and surgeon, greatly affected all of us here in Pittsburgh as well as many researchers across the country who had the opportunity to work with him.

NRG Oncology Member News
Norman Wolmark, MD, receives 2019 Ezra Greenspan Award

Dr. Norman Wolmark, an NRG Oncology group chair, received the Ezra Greenspan Award at The Chemotherapy Foundation's 2019 Innovation Gala that was held November 6, 2019, at The Russian Tea Room in New York City.  Read more
Protocol Support Committee Column 

Introduction to Clinical Trials: Principles of NRG Oncology Clinical Trial Management for Nurses and CRAs

If you are a nurse or clinical research associate (CRA) who is new to NRG Oncology, you may want to consider attending the orientation session being held on Thursday, January 9, 2020, at the NRG Oncology Semiannual meeting in Houston. 
Registration is Open for #NRG2020 
Be sure to pay close attention to the agenda as sessions have changed times since our previous meetings. Registration fees are waived for attendees who register online prior to the meeting! 
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse